Serotonin syndrome: not a benign toxidrome

Philippe Birmes and associates¹ suggest that serotonin syndrome is a less serious condition than neuroleptic malignant syndrome (NMS), but this has not been our experience.²⁻⁵ In our prospective study of serotonin syndrome,¹⁶ 6 of the 16 patients experienced disseminated intravascular coagulation (DIC), rhabdomyolysis and hypotension necessitating admission to the intensive care unit. Acute renal failure developed in 2 patients, and 1 patient died.

Table 2 in the article by Birmes and associates¹ does not capture the key differences between NMS and serotonin syndrome. Both conditions can be fulminant, and patients may present with delirium, hyperthermia, rhabdomyolysis, dilated pupils, tachycardia, diaphoresis, rigidity and blood pressure changes²⁻⁵ (see Table 1 with this letter). The main difference lies in the clinical gestalt: typically a patient with serotonin syndrome is agitated, speaks incoherently and has prominent myoclonus, whereas a patient with NMS is immobile, mute and staring. Although rhabdomyolysis is a complication of both toxidromes, DIC, seizures, ventricular tachycardia and severe hypotension are extremely rare in NMS.²

We agree with the mainstays of treatment suggested by Birmes and associates¹ but we also advise monitoring of vital signs, platelet count, muscle enzymes and myoglobin twice daily for at least 72 hours. We have serious concerns about the use of chlorpromazine and propranolol for serotonin syndrome. Both drugs decrease blood pressure, which will exacerbate the hard-to-treat hypotension that can occur in serotonin syndrome; in addition, chlorpromazine may precipitate NMS. An absolute contraindication for the use of propranolol is a history of asthma, which is difficult to elicit if the patient is delirious. Finally, it is important to advise patients taking serotonergic agents about the risks of this potentially serious and fulminant syndrome.

Sarah Garside
Clinical Scholar
Patricia I. Rosebush
Associate Professor
Department of Psychiatry and
Behavioural Neuroscience
McMaster University
Hamilton, Ont.

References

Competing interests: None declared.

Smith-Magenis syndrome

Waleed Al Busairi and Fawzi Ali describe a 15-year-old boy with mental retardation and a history of putting inedible objects into his mouth. The authors might want to investigate

Table 1: Clinical characteristics, laboratory abnormalities, complications, and risk factors for neuroleptic malignant syndrome and serotonin syndrome²⁻⁵

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Neuroleptic malignant syndrome</th>
<th>Serotonin syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical clinical presentation</td>
<td>Rigid, mute, staring, immobile</td>
<td>Agitated, incoherent speech, myoclonic twitching, bruising</td>
</tr>
<tr>
<td>Cognitive</td>
<td>Mild confusion to delirium; difficult to assess because of mutism</td>
<td>Mild confusion to delirium</td>
</tr>
<tr>
<td>Autonomic</td>
<td>Fever, tachycardia, diaphoresis, dilatation of pupils, blood pressure instability</td>
<td>Fever, tachycardia, diaphoresis, dilatation of pupils, blood pressure instability (hypertension in moderate cases, hypotension in severe cases)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Constipation, ileus</td>
<td>Nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Severe muscular rigidity (cogwheel), rigours, tremulousness</td>
<td>Hyperreflexia, myoclonus, tremulousness, clonus, fasciculations, ataxia, with or without rigidity</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Facial expression “fearful,” underlying psychosis, premorbid mood disorder</td>
<td>Underlying mood or anxiety disorder; delirium may be misinterpreted as psychosis</td>
</tr>
<tr>
<td>Common laboratory abnormalities</td>
<td>Leukocytosis, elevation of muscle enzymes (CPK, ALT, AST, LDH), low serum iron</td>
<td>Leukocytosis, elevation of muscle enzymes (CPK, ALT, AST, LDH), thrombocytopenia</td>
</tr>
<tr>
<td>Complications</td>
<td>Aspiration pneumonia, renal failure, pulmonary embolus, contractures, postepisode muscle weakness</td>
<td>Falls, seizures, severe hypotension, ventricular tachycardia, disseminated intravascular coagulation, renal failure, coma (mortality rate unknown)</td>
</tr>
<tr>
<td>Risk factors</td>
<td>Antipsychotic drug use (all types), polypharmacy, rapid increase in neuroleptic dosage, concurrent use of lithium, dehydrogenation, catatonia, agitation, benzodiazepine withdrawal during neuroleptic treatment</td>
<td>Use of serotonergic agents (all types), polypharmacy, concurrent use of lithium, MAOIs plus demerol (other risk factors unknown)</td>
</tr>
</tbody>
</table>

Note: CPK = creatine phosphokinase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, LDH = lactic dehydrogenase, MAOIs = monoamine oxidase inhibitors.
for Smith-Magenis syndrome if this has not previously been considered.

Smith-Magenis syndrome is associated with mental retardation, sleep disturbances, few facial dysmorphic features, self-injurious behaviour and putting objects into orifices. This trait of bodily insertions is known as polyembolokoilamania. The definitive diagnosis is based on absence of the 17p11.2 region (a band on the short arm of chromosome 17), determined by cytogenetic examination (in more than 95% of cases) or by fluorescence in situ hybridization (also known as FISH).

Chitra Prasad
Medical Genetics Program of Southwestern Ontario
London Health Sciences Centre London, Ont.

References

We did not consider Smith-Magenis syndrome for the patient described in our article. This chromosomal microdeletion syndrome is associated with a clinically recognizable pattern of physical, developmental and behavioural features. The facial appearance is characterized by broad, square shape, brachycephaly, prominent forehead, synophrys, up-slanting palpebral fissures, deep-set eyes, broad nasal bridge, midfacial hypoplasia and prognathism. The behavioural phenotype includes sleep disturbance, attention deficit disorders, attention-seeking, aggression, self-injurious behaviour and stereotypes, especially the self-hug and lick-and-flip movements.

We suspect that Chitra Prasad raised the possibility of Smith-Magenis syndrome because the patient was mentally retarded and ingested foreign bodies. However, 2 important distinctions must be made. First, most people with Smith-Magenis syndrome have mild to moderate mental retardation, whereas this patient had severe to profound retardation. Second, the syndrome is associated with polyembolokoilamania, the insertion of objects into body orifices such as the rectum, vagina, urethra, nose and ear, rather than pica, in which ingestion is restricted to the oral route, as in the patient we described. Smith-Magenis syndrome is rare, occurring in 1 of 25 000 births, but pica affects some 20% of mentally retarded people.

Other facts about this patient, not given in the article, made a diagnosis of Smith-Magenis syndrome unlikely. For example, the patient did not show the distinctive facial appearance or behavioural phenotype of this syndrome. Furthermore, virtually all cases of Smith-Magenis syndrome occur de novo, whereas the patient’s family included other mentally retarded siblings, which indicated an inherited abnormality.

Fawzi E. Ali
Medical Rehabilitation Center UN Square
Al-Sabah Health Zone
Kuwait

References

Correction
In a recent article on adaptation of Inuit children to a low-calcium diet, the units for the urinary calcium to creatinine ratio were given incorrectly. The units in the text and the table should have been moles per mole (mol/mol). Note that the numeric values for both the study results and the normative values are correct as presented.

Reference

New letters submission process
CMAJ’s enhanced eLetters feature is now the portal for all submissions to our letters column. To prepare an eLetter, visit www.cmaj.ca and click “Submit a response to this article” in the box near the top right-hand corner of any eCMAJ article. All eLetters will be considered for publication in the print journal.

Letters written in response to an article published in CMAJ are more likely to be accepted for print publication if they are submitted within 2 months of the article’s publication date. Letters accepted for print publication are edited for length (usually 250 words) and house style.